Amgen (AMGN) : Manufacturers Life Insurance Company The scooped up 66,607 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 3,433,014 shares of Amgen which is valued at $593,980,082.Amgen makes up approximately 0.87% of Manufacturers Life Insurance Company The’s portfolio.
Other Hedge Funds, Including , Wellington Shields Capital Management reduced its stake in AMGN by selling 3,000 shares or 55.81% in the most recent quarter. The Hedge Fund company now holds 2,375 shares of AMGN which is valued at $410,923. Amgen makes up approx 0.07% of Wellington Shields Capital Management’s portfolio.Meiji Yasuda Life Insurance Co boosted its stake in AMGN in the latest quarter, The investment management firm added 1,090 additional shares and now holds a total of 18,207 shares of Amgen which is valued at $3,150,175. Amgen makes up approx 0.48% of Meiji Yasuda Life Insurance Co’s portfolio. Engineers Gate Manager Lp sold out all of its stake in AMGN during the most recent quarter. The investment firm sold 16,749 shares of AMGN which is valued $2,897,912.Oxbow Advisors reduced its stake in AMGN by selling 1,624 shares or 9.28% in the most recent quarter. The Hedge Fund company now holds 15,874 shares of AMGN which is valued at $2,753,028. Amgen makes up approx 0.39% of Oxbow Advisors’s portfolio.Boston Private Wealth boosted its stake in AMGN in the latest quarter, The investment management firm added 3,435 additional shares and now holds a total of 111,970 shares of Amgen which is valued at $19,418,957. Amgen makes up approx 0.77% of Boston Private Wealth’s portfolio.
Amgen opened for trading at $170.55 and hit $170.56 on the upside on Thursday, eventually ending the session at $170.13, with a gain of 0.04% or 0.07 points. The heightened volatility saw the trading volume jump to 18,76,141 shares. Company has a market cap of $127,319 M.
On the company’s financial health, Amgen reported $2.84 EPS for the quarter, beating the analyst consensus estimate by $ 0.10 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $2.74. The company had revenue of $5688.00 million for the quarter, compared to analysts expectations of $5579.33 million. The company’s revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.57 EPS.
Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.
Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.